SCHEDULE 13G/A: BlackRock Discloses 1.6% Passive Stake in Atossa Therapeutics
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.6% beneficial ownership stake in Atossa Therapeutics, Inc.'s common stock as of June 30, 2025.
Summary
- BlackRock, Inc. beneficially owns 2,094,891 shares of Atossa Therapeutics, Inc. common stock.
- This ownership represents 1.6% of Atossa Therapeutics, Inc.'s outstanding common stock.
- BlackRock holds sole voting power over 2,092,131 shares and sole dispositive power over 2,094,891 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Atossa Therapeutics, Inc.
- The filing is an Amendment No. 1 to a previous Schedule 13G statement.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing reporting beneficial ownership, which inherently carries a neutral sentiment. It does not contain qualitative statements or performance metrics that would indicate positive or negative sentiment.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Atossa Therapeutics, Inc.'s future outlook.
Management Comments
- BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a routine disclosure of passive institutional ownership by a major asset manager, BlackRock, in a publicly traded biotechnology company, Atossa Therapeutics. It reflects BlackRock's investment activities rather than specific industry trends or competitive dynamics.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. issued a new Power of Attorney, effective January 21, 2025, revoking a previous one dated April 30, 2023. This new Power of Attorney authorizes specific individuals to execute and file documents related to ownership or control-person reporting requirements on behalf of BlackRock and its affiliates. | 2025-01-21 | Streamlines the process for BlackRock's authorized individuals to comply with various regulatory reporting requirements, including SEC filings like Schedule 13G. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company, which may influence investor perception and confidence.
- Management: Confirms that BlackRock's investment is for passive purposes and not intended to influence control.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney revoked by the new Power of Attorney. |
| 2025-01-21 | Date of the new Power of Attorney granted by BlackRock, Inc. |
| 2025-06-30 | Date of event which requires the filing of this statement, reflecting BlackRock's beneficial ownership. |
| 2025-07-16 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
BlackRock, Atossa Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.